Europe Viscosupplementation Market is expanding rapidly with Fidia Pharma USA Inc. launching TRILURON, a hyaluronic acid (HA)-based intra-articular viscosupplement indicated for the treatment of pain in osteoarthritis of the knee

Europe Viscosupplementation Market

Viscosupplementation is the term used for decompressing a spinal joint. As a result of this, the pressure on surrounding structures decreases, allowing for easier movement within the joint. Another key factor aiding growth of the said market is rapidly rising geriatric population. Elderly people are most vulnerable to orthopedic diseases due to weakened bones. As per the Eurostat, in 2020, over 20.6% of the EU population was aged 65 years and above. Thus, elderly people are more likely to suffer from orthopedic diseases such as osteoarthritis, osteoporosis, and more. Hence, such factors can augment growth of the Europe viscosupplementation market. Recently, in December 2019, Fidia Pharma USA Inc. launched TRILURON, a hyaluronic acid (HA)-based intra-articular viscosupplement indicated for the treatment of pain in osteoarthritis of the knee.

Viscosupplementation is not a cure-all. It is most effective when used after other treatments have failed. In fact, to date, there are still no studies comparing osteoarthritis sufferers with those who undergo Viscosupplementation before, during, and after therapy. However, it has been shown to be much safer and more effective than many of the other osteoarthritis injections and medications currently on the market. With growing prevalence of osteoarthritis (OA) has led to increasing in demand for viscosupplementation. Osteoarthritis refers to the type of arthritis that occurs when flexible tissue at the ends of bone wears down. As per the National Institute of Health and Care Excellence (NICE), in the U.K., around 8.5 million people suffer from painful joints due to osteoarthritis every year. Such a high prevalence of osteoarthritis has led to increased demand for hip and knee treatment. Hence, such factors can stimulate growth of the Europe viscosupplementation market.

If Viscosupplementation is successful in providing pain relief in the joint by allowing cartilage to break down, it will also increase the amount of available cartilage. This allows the formation of new, healthier cartilage that should heal the damaged joints and restore normal functioning to them. Regardless of these factors, there are certain challenges that remain prevalent that can limit growth of the market. For instance, side effects associated with viscosupplementation include bruising around joints, swelling, and injection-side pain could impede growth of the Europe viscosupplementation market. However, many companies operating in the market are focused on research and development activities, in order to innovate effective treatment options. Such factors can provide significant growth opportunities in the Europe viscosupplementation market in the near future.

Comments

Popular posts from this blog

U.S. Meibomian Gland Dysfunction Market is growing rapidly with ThermaMEDx introducing a self-healing, disposable, pre-moistened, sterile cleaning eye-pad for use in treating the symptoms of dry eyes and meibomian gland dysfunction

Boston Sci Launched A New Device For Erectile Dysfunction Devices Market

Bakeable Trays Market Estimated To Develop At Cagr at 4.8% During Estimate Duration 2019-2027